BERLIN (Reuters) -German pharma company Bayer reported positive study results for its anticoagulant asundexian on Sunday, two years after a research setback for the promising blood thinner candidate.
In a Phase III study, a daily dose of 50 milligrams significantly reduced the risk of ischemic stroke compared with a placebo, Bayer said.
Detailed results from the OCEANIC-STROKE study will be presented at an upcoming scientific congress, said Bayer.
Bayer added that it plans to speak with health authorities worldwide in preparation for the submission of marketing authorisation applications.
Bayer had originally predicted that asundexian would have peak sales potential of more than 5 billion euros ($5.76 billion) - more than any of its other drugs.
At the end of 2023, the company had a major setback with the drug after it failed in a pivotal clinical trial involving patients with atrial fibrillation and a risk of stroke.
($1 = 0.8687 euros)
(Reporting by Joern Poltz. Writing by Miranda Murray. Editing by Jane Merriman)
latest_posts
- 1
Which Store is Your Decision ? - 2The most effective method to Guarantee Thorough Inclusion in Senior Protection.
- 3Figure out How to Introduce Sunlight powered chargers on Your Rooftop securely
- 45 Eating routine Well disposed Snacks to Keep You Fulfilled
- 5AstraZeneca to invest $2 billion as part of US manufacturing push
- They died 'doing what they loved': The stories of workers in their 80s who died on the job
- 5 Worldwide Road Food varieties You Should Attempt
- IDF uncovers 7 km.-long Gaza terror tunnel where Hamas held Hadar Goldin
- Visiting This Japanese City Just Got A Little More Expensive (Here's What Travelers Should Know)
- Manual for Tracking down One of a kind Store Inns
- Grass Care Administrations for a Wonderful, Sound Yard
- The 15 Best Business visionaries Under 40
- Well known SUVs With Low Energy Utilization In 2024 vote
- Little Urban communities to Visit in Western Europe
